Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQ-1021
- Development stage
- Preclinical
- Lead developer
- TheraQuest Biosciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
TQ-1021 is a proprietary topical formulation of the local anesthetic **mepivacaine** developed by TheraQuest Biosciences for the treatment of **neuropathic pain**. As a sodium channel blocker, it provides localized anesthesia by inhibiting nerve impulse generation and conduction in sensory nerves, targeting peripheral neuropathic conditions with reduced systemic exposure compared to injectable forms.[1][3][11]
- Other names
- REL-1021REL1021REL 1021MepiGel
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on TQ-1021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQ-1021.